Endurance exercise reduces hepatic fat content and serum fibroblast growth factor 21 levels in elderly men

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 1, 2016, Pages 191-198

  Taniguchi, Hirokazu ^a   Tanisawa, Kumpei ^a,b   Sun, Xiaomin ^a   Kubo, Takafumi ^a   Higuchi, Mitsuru ^a,c  

^a WASEDA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c Institute of Advanced Active Aging Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSSOVER PROCEDURE; ENDURANCE TRAINING; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT CONTENT; HUMAN; JAPANESE (PEOPLE); LIVER LEVEL; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION; ANTHROPOMETRY; BLOOD; BODY COMPOSITION; CYCLING; ENDURANCE; EXERCISE; FITNESS; LIPID METABOLISM; LIVER; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY;

AGED; ANTHROPOMETRY; BICYCLING; BODY COMPOSITION; CROSS-OVER STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE; FIBROBLAST GROWTH FACTORS; HUMANS; LIPID METABOLISM; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PHYSICAL ENDURANCE; PHYSICAL FITNESS;

EID: 84954528539     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3308     Document Type: Article

References (40)

1. Fan JG, Farrell GC. Does non-alcoholic fatty liver disease predispose patients to type 2 diabetes in the absence of obesity? J Gastroenterol Hepatol. 2010;25:223-225.
2. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363:1341-1350.
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344.
4. Cree MG, Newcomer BR, Katsanos CS, Sheffield-Moore M, et al. Intramuscular and liver triglycerides are increased in the elderly. J Clin Endocrinol Metab. 2004;89:3864-3871.
5. Kharitonenkov A, Shanafelt AB. FGF21: A novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs. 2009; 10:359-364.
6. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59:2781-2789.
7. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology. 2012;153:69-80.
8. Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2011;96:E351-E355.
9. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53:934-940.
10. Hanks LJ, GutierrezOM,BammanMM,Ashraf A, McCormick KL, Casazza K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl Hepatol. 2015;2:77-82.
11. Taniguchi H, Tanisawa K, Sun X, et al. Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men. J Clin Endocrinol Metab. 2014;99:E1877-E1884.
12. Chen C, Cheung BM, Tso AW, et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: A 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011;34:2113-2115.
13. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36:145-149.
14. Ong KL, Januszewski AS, O'Connell R, et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015;58:464-473.
15. Hannukainen JC, Borra R, Linderborg K, et al. Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. J Hepatol. 2011;54:545-552.
16. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009;58:1281-1288.
17. Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20:17932-17940.
18. Kim HJ, Lee KE, Kim DJ, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164:2169-2175.
19. Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17:1098-1105.
20. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43:1334-1359.
21. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139:456-463.
22. Yang SJ, Hong HC, Choi HY, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011;75:464-469.
23. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203-206.
24. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426-437.
25. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627-1635.
26. Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271-281.
27. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282:26687-26695.
28. OgawaY, Kurosu H, YamamotoM,et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21 Proc Natl Acad Sci U S A. 2007;104:7432-7437.
29. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol. 2008;215:1-7.
30. Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22: 1006-1014.
31. Samson SL, Sathyanarayana P, Jogi M, et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011;54:3093-3100.
32. Yu Y, Zhang XH, Ebersole B, Ribnicky D, Wang ZQ. Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice. Sci Rep. 2013;3:3142.
33. Cho J, Lee I, Kim D, et al. Effect of aerobic exercise training on non-alcoholic fatty liver disease induced by a high fat diet in C57BL/6 mice. J Exerc Nutrition Biochem. 2014;18:339-346.
34. Sawada SS, Lee IM, Naito H, et al. Long-term trends in cardiorespiratory fitness and the incidence of type 2 diabetes. Diabetes Care. 2010;33:1353-1357.
35. Lee DC, Sui X, Artero EG, et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: The Aerobics Center Longitudinal Study. Circulation. 2011;124:2483-2490.
36. Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS. Acute exercise induces FGF21 expression in mice and in healthy humans. PloS One. 2013;8:e63517.
37. Martin WH 3rd, Dalsky GP, Hurley BF, et al. Effect of endurance training on plasma free fatty acid turnover and oxidation during exercise. Am J Physiol. 1993;265:E708-E714.
38. Yu H, Xia F, Lam KS, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem. 2011;57:691-700.
39. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett. 2008;582:3805-3810.
40. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18:237-243.